Видео с ютуба Periop Durvalumab

Perioperative Durvalumab in Bladder Cancer | NEJM

AEGEAN Trial: Perioperative Durvalumab for NSCLC - OncTalk Lung 2023

NIAGARA: perioperative durvalumab with neoadjuvant chemotherapy in MIBC

Perioperative durvalumab in addition to neoadjuvant chemotherapy shows positive results in patie...

NIAGARA: ctDNA in Patients With MIBC Who Received Perioperative Durvalumab

NIAGARA Trial - Periop Durvalumab with Neoad Chemo Resectable Muscle-Invasive Bladder Cancer

NIAGARA: Результаты оценки качества жизни при периоперационном применении дурвалумаба у пациентов...

Perioperative Durvalumab FDA Approval New Standard for Muscle Invasive Bladder Cancer

NIAGARA: Perioperative Durvalumab Shows Overall Survival Benefit in Muscle-Invasive Bladder Cancer

The impact of durvalumab on the SCLC treatment landscape

Perioperative Durvalumab Appears Safe for Locally Advanced RCC - Medpage Today

Perioperative durvalumab plus FLOT improves outcomes in gastric cancer

Perioperative durvalumab and FLOT chemo can reduce risk of recurrence for some gastric cancers

NIAGARA: impact of pCR on outcomes of durvalumab with NAC in MIBC

NIAGARA - New Standard for Muscle Invasive Bladder Cancer with Neoadj Chemo & Periop Durvalumab

AEGEAN Trial: Perioperative Durvalumab & ctDNA Clearance in Resectable NSCLC – WCLC/ESMO 2024

MATTERHORN: improved pCR with the use of durvalumab + FLOT in resectable GC/GEJC

NIAGRA: Bladder-Sparing Potential of Perioperative Immunotherapy

Durvalumab / Imfinzi (NIAGRA Trial) Defies Odds in MIBC Survival Benefits Beyond Complete Response

Primary analysis of SAKK 06/17: perioperative chemoimmunotherapy with durvalumab for operable MIUC